Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.
An analysis is presented to compare the efficacies of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) and tamsulosin in patients with benign prostatic hyperplasia (BPH), collecting data from a published 20-week, randomized, double-blind, crossover study. Results demonstrated that after 8 weeks of treatment, both doxazosin-GITS and tamsulosin provided significant (p < 0.001) improvement from baseline in total international prostate symptom score (IPSS) and obstructive and irritative subscores. Doxazosin-GITS was more effective than tamsulosin (p = 0.019 between-group difference for total IPSS; p = 0.001 for irritative subscore). Similarly, after the first 4 weeks of treatment, prior to dose titration, both doxazosin-GITS and tamsulosin provided significant (p < or = 0.001) improvement in total IPSS and subscores. Doxazosin-GITS was more effective than tamsulosin (p = 0.045 between-group difference for obstructive subscore). These data confirm that the efficacy of doxazosin is superior to that of tamsulosin in the management of patients with BPH.
Kirby
R S
RS
Department of Urology Research, Ingleby House, St. George's Hospital, Blackshaw Road, London, UK. rogerkirby@compuserve.com
Quinn
S
S
Mallen
S
S
Jensen
D
D
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D017292:Doxazosin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D003692:Delayed-Action Preparations; D013449:Sulfonamides; D000077409:Tamsulosin; D017292:Doxazosin